

Stockholm, April 29, 2009

Annual Report SCN 2008

Scandinavian Clinical Nutrition i Sverige AB (publ) releases the Annual Report for 2008.

From today onwards, the 2008 Annual Report of Scandinavian Clinical Nutrition AB is available on the company's website www.scnnutrition.com. A paper version can be ordered via mail (SCN AB, Stora Nygatan 7, Stockholm), via phone +46 8 586 107 80, via fax +46 8 222 006, or via e-mail info@scnnutrition.com.

The Annual General Meeting takes place in Stockholm on June 26, 2009.

In comparison with the information presented in the unaudited Year-End and Q4 Report, one event has taken place that requires adjustment of and disclosure in the financial statements or notes. On April 2, 2009, SCN communicated that the Company had entered into a LOI with PhytoLab Solutions, Inc., part of the Lifequest group, which extended the standstill agreement regarding their option to acquire the SCN subsidiary containing the rights to Immulina against a further upfront consideration of USD 1 million in Lifequest shares. Due to this agreement, the upfront payment of USD 1 million in Lifequest shares received by SCN during Q4, 2008, will not be cashed during Q1, 2009, which changes the group's consolidated cash flow statement negatively with USD 7.8 million.

Furthermore, an error has been discovered in the group balance sheet, where the goodwill was undervalued in the year-end and Q4 report. The correct valuation is USD 27.7 million, instead of USD 19.4 million as was written in the year-end and Q4 report.

The Board also again wants to highlight the adjustments which were made in the year-end and Q4 report in comparison to the Q3 report:

- During Q4, parts of the balance sheet were re-evaluated, for example, new assessments have been made regarding the previously capitalized tax asset of MSEK 10.2 and an item previously reported as advance payment of MSEK 7.1, both now reverted. The reversal of the tax asset affects the Q4 result, and the advance payment item affects both Q4 and full year 2008.
- During Q4, the sale of 13.5% of SCN's shareholding in Scandivir was approved by an Extraordinary General Meeting. This transaction was erroneously reported as carried out during Q3 in the Q3 report.

For more information, please contact:

Ulf Söderberg, CEO, us@scnnutrition.com, +46 708 13 22 81

Jörn Erik Aas, Chairman of the Board, jea@scnnutrition.com, +47 924 99 360

Scandinavian Clinical Nutrition i Sverige AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker "SCN" on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se). For more information, please visit www.scnnutrition.com.